

**IN THE CLAIMS:**

**LISTING OF THE CLAIMS:**

Claims 1-106 Cancelled

107(new): An immunoassay method for analysis of a sample, comprising the steps of:

- a. contacting the sample with a monoclonal antibody specifically recognizing human iNOS enzyme without cross-reacting with human nNOS or human eNOS; and
- b. detecting the presence of human iNOS protein in said sample, said monoclonal antibody recognizing human iNOS protein.

108(new): A binding assay method for analysis of a sample, comprising the steps of:

- a. contacting the sample with a binding entity specifically reactive to a region of human iNOS without cross-reacting with human nNOS or human eNOS,
- b. detecting the presence of a region of human iNOS protein in said sample, said binding entity specifically recognizing a region of human iNOS protein, without cross-reacting with human nNOS or human eNOS.

109(new): The method of claim 108 in which said binding entity of said region of human iNOS protein comprises a peptide analogue having the sequences selected from the group consisting of: NNNVEKAPCATSSPVTQD (SEQ ID NO 32), SPVTQDDLQYHNLSKQQN (SEQ ID NO 26), NNNVEKAPCATSSPVTQD plus SPVTQDDLQYHNLSKQQN (SEQ ID NO

29), PALVQGILERVVDGPTPH (SEQ ID NO 30), GIVPFRSFWQQLHDSQH (SEQ ID NO 25), and RMTLVFGSRRPDEDHITQ (SEQ ID NO 31).

110(new): The method of claim 107 in which said immunoassay is selected from the group comprising: direct, indirect, capture, competitive binding, and displacement.

111(new): The method of claim 107 in which said step of detecting the presence of human iNOS protein comprises a qualitative analysis.

112(new): The method of claim 107 in which said step of detecting the presence of human iNOS comprises a quantitative analysis.

113(new): The method of claim 107 in which said binding assay comprises a clinical diagnostic assay.

114(new): The method of claim 107 which is of the type selected from the group consisting essentially of: IFA, linear flow, radial flow, Western Blot, ELISA, dip stick, EIA, fluorescent polarization, enzyme capture, and RIA.

115(new): The method of claim 108 in which said binding assay is selected from the group comprising: direct, indirect, capture, competitive binding, and displacement.

116(new): The method of claim 108 in which said step of detecting the presence of human iNOS protein comprises a qualitative analysis.

117(new): The method of claim 108 in which said step of detecting the presence of human iNOS comprises a quantitative

analysis.

118(new): The method of claim 108 in which said binding assay comprises a clinical diagnostic assay.

119(new): The method of claim 108 which is of the type selected from the group consisting essentially of: IFA, linear flow, radial flow, Western Blot, ELISA, dip stick, EIA, fluorescent polarization, enzyme capture, and RIA.

120(new): The method of claim 108 in which said specific binding entity is a peptide analogue having the sequence: VTQDDLQ (SEQ ID NO 89).

121(new): The method of claim 108 in which said specific binding entity is a peptide analogue having the sequence: VQGILERV (SEQ ID NO 120).

*Rule 1.126*  
*122* 122(new): A binding assay for iNOS contained in a sample comprising:

a. a specific binding entity reactive to human iNOS enzyme without cross-reacting with human nNOS or human eNOS; and

b. a vehicle for revealing the presence of human iNOS according to said specific binding entity recognizing a region of human iNOS protein.